NEW ORLEANS, July 14, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 28, 2017 to file lead plaintiff applications in a securities class action lawsuit against Mattel, Inc. (Nasdaq:MAT), if they purchased the Company’s securities between October 20, 2016 and April 20, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
Get Help
Mattel investors should visit us at https://www.claimsfiler.com/cases/view-mattel-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Mattel and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 19, 2016, Mattel announced positive results for Q3 2016. However, the Company failed to disclose that it had issued an excessive level of inventory to its retailers which, although temporarily inflating revenue, required the Company to later make significant sales adjustments and discounts to clear the excess product and ultimately resulted in a material negative impact on performance. As a result, on April 20, 2017, Mattel revealed dismal financial results for Q1 2017, well below Wall Street consensus estimates.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Apple Turns 50: From Garage Startup to AI Crossroads
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
First Western Ship Transits Strait of Hormuz Since Iran War Began
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 



